Marked, Homogeneous, and Early [(18)F]Fluorodeoxyglucose–Positron Emission Tomography Responses to Vemurafenib in BRAF-Mutant Advanced Melanoma

PURPOSE: Imaging with [(18)F]fluorodeoxyglucose (FDG) –positron emission tomography (PET) allows early recognition of a response to agents that target key driver mutations in human cancer. We aimed to determine the metabolic response rate to vemurafenib in patients with advanced BRAF-mutant melanoma...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Oncol
Autors principals: McArthur, Grant A., Puzanov, Igor, Amaravadi, Ravi, Ribas, Antoni, Chapman, Paul, Kim, Kevin B., Sosman, Jeffrey A., Lee, Richard J., Nolop, Keith, Flaherty, Keith T., Callahan, Jason, Hicks, Rodney J.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2012
Matèries:
Original Reports
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5950495/
https://ncbi.nlm.nih.gov/pubmed/22454415
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.39.1938
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars